In The News
Hytera can’t dodge finding it committed ‘industrial theft’ of Motorola’s source code
CIMIC settles shareholder class action for $45.25M
Judge approves $31.5M settlement in junior doctors class action
Meriton to face more evidence of alleged $8M defects at Symphony apartments
ASIC claims crypto firm Binance denied protections to derivatives investors
Aldi infringed copyright of Little Bellies fruit snacks, court finds
Barrister who accepted briefs for appearances on same day referred to watchdog
Melbourne law firm argues 700 clients can’t sue for negligence in class action
Hall & Wilcox brings on Moray & Agnew public law specialist
Slashing funder’s stolen wages cut could deter public interest cases, court told
Please login to bookmarkClose

Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling the Federal Court on Friday it denied its rival’s claims.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au